Viking Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update
Viking Therapeutics, Inc. ("Viking") (NASDAQ: VKTX), a clinical-stage biopharmaceutical company focused on the development of novel therapies for metabolic and endocrine disorders, today announced its ...
Nasdaq9d
Zenas BioPharma Advances Obexelimab Trials and Out-licenses Thyroid Eye Disease Programs in 2024 Update
Out-licensing its greater-China anti-IGF-1R thyroid eye disease programs to Zai ... patients in the MoonStone trial are being randomized 2:1 to 250 mg of obexelimab or placebo administered as ...
CNET on MSN8d
6 Important Blood Tests for Comprehensive Health
These are the most important blood tests that doctors suggest you should have for a deep dive into your health.
Viking Therapeutics, Inc.: Viking Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update
Conference call scheduled for 4:30 p.m. ET today Initiation of Phase 3 Studies for Subcutaneous VK2735 for Obesity Planned for 2Q25 Phase 2 VENTURE-Oral Dosing Trial ...
Medscape8d
Look out for Lugol's… Error-prevention Strategies for this Strong Iodine Solution
Recently, ISMP Canada published a safety bulletin on oral dosing errors associated with LUGOL's solution (potassium iodide and iodine), also referred to as strong iodine solution. [1] The ...
MarketBeat on MSN9d
Amgen Earnings Transcript (NASDAQ:AMGN)
Presentation Unidentified Speaker Thank you. Thank you, Julianne. Good afternoon, everyone, and welcome to our 4th-quarter ...
PharmiWeb9d
FDA approves Roche’s Susvimo as the first and only continuous delivery treatment for the leading cause of diabetes-related blindness
Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today that the US Food and Drug Administration (FDA) has approved Susvimo® (ranibizumab injection) 100 mg/mL for the treatment of diabetic macular edema ...
Pharmabiz8d
Roche’s Susvimo receives US FDA approval for the treatment of diabetic macular edema
Roche’s Susvimo receives US FDA approval for the treatment of diabetic macular edema: Basel Thursday, February 6, 2025, 11:00 Hrs [IST] Roche announced that the US Food and Drug ...
Frontiers5d
When thyroid met brain: the enigma of steroid responsive encephalopathy associated with autoimmune thyroiditis a case report
Her thyroid profile was also normal ... was managed with an intravenous bolus of labetalol (20 mg), achieving a controlled reduction to 180/100 mmHg. Upon presentation, blood glucose levels were ...